Tern Positive Traction and Growth Highlights Progressive Research’s Gareth Evans

Tern plc

Company Overview

Tern PLC (LON:TERN), operates a hybrid venture capital model that focuses on disruptive Internet of Things (IoT) start-ups with proven technologies. As of 31 December 2023, the company’s market capitalisation stood at £12.1 million, with a net cash position of £0.3 million and an enterprise value of £11.8 million. The company is led by Chairman Ian Ritchie, CEO Albert E. Sisto, and CFO Colin Nunn.

Key Performance Metrics and Financial Health

Tern’s financial year 2023 (FY23) results demonstrate significant improvements in key performance indicators (KPIs), although the company has faced valuation challenges in a globally depressed technology sector. Despite these headwinds, Tern’s portfolio companies have shown substantial commercial traction and growth in annual recurring revenue (ARR).

  • Annual Recurring Revenue Growth: ARR increased by 50% in FY23, with a concurrent 51% rise in ARR per employee.
  • Portfolio Valuations: However, the overall valuation of Tern’s investments declined by £11.1 million due to various factors, including investment disposals, foreign exchange impacts, and negative movements in fair value of investments.

The financial summary indicates:

  • A total comprehensive loss of £12.6 million for FY23, primarily due to net negative fair value movements.
  • Net assets fell to £12.5 million, a 50% decline from the previous year.
  • Year-end cash balance stood at £298,000, down from £932,000 in FY22.

Operational Highlights and Portfolio Performance

Tern’s portfolio companies have made significant strides, each carving out leadership positions in their respective markets:

  • Device Authority: Valued at £4.4 million (down from £11.9 million), Device Authority has expanded its ARR significantly and aims to triple it in the coming year, driven by strategic partnerships with major players like Microsoft and Entrust.
  • Wyld Networks: Valued at £2.4 million (down from £6.0 million), Wyld Networks has launched Wyld Fusion, a hybrid terrestrial and satellite platform, and begun shipping Wyld Terminals. Its total addressable market is estimated at $4.3 billion.
  • FundamentalVR: Maintaining a valuation of £3.6 million, FundamentalVR has seen continued ARR growth and strong client retention, with notable partnerships in the medical field and visibility in Meta’s global campaigns.
  • Talking Medicines: Increased in value to £2.0 million from £1.8 million, Talking Medicines leverages AI to source patient feedback and has successfully expanded into the US market with a growing SaaS subscription base.
  • Konektio: Written off with no current valuation, reflecting its entry into administration.
  • Diffusiondata: A minor investment, valued at £0.02 million.
  • SVVUK: Valued at £0.3 million, up from £0.1 million.

Expert Analysis by Progressive Equity Research

According to Gareth Evans, an analyst at Progressive Equity Research, Tern’s FY23 results highlight a notable improvement in performance metrics, which is expected to attract additional strategic interest across the portfolio. Evans notes that despite the significant improvement in performance metrics, the valuation decline is reflective of broader market trends in the technology sector. He emphasises that Tern’s funding-to-exit model requires patience, with all portfolio companies now firmly into their growth stage and leaders in their targeted markets.

Evans comments, “Tern’s strategy of focusing on high-growth sectors and supporting entrepreneurs with essential capital is showing results, despite the challenging economic environment. The company’s emphasis on expanding sales operations and securing strategic partnerships is key to its future success.”

Strategic Outlook and Future Prospects

Tern’s management remains committed to pursuing high-growth opportunities by supporting entrepreneurs with necessary capital while driving value creation through strategic exits. The challenging economic environment necessitates a focus on sustainability and reducing burn rates, rather than aggressive market dominance.

The company’s strategy emphasises:

  • Expanding sales operations to enhance market presence.
  • Participating in fundraises where possible to avoid dilution.
  • Negotiating favourable terms with new investors to facilitate successful exits.

Despite the valuation challenges, Tern’s portfolio companies are positioned for substantial growth, with significant momentum as they enter the next phase of their development.

Final Thoughts

Tern PLC continues to navigate a complex and evolving technology landscape, leveraging its hybrid venture capital model to support and grow disruptive IoT start-ups. The company’s focus on improving KPIs and strategic partnerships positions it well for future growth, although the near-term outlook remains tempered by broader market valuation trends. As Tern’s portfolio companies mature and achieve further commercial traction, the potential for value creation remains substantial, offering diversified exposure to innovative IoT-related assets for shareholders.

Evans concludes, “We remain optimistic about Tern’s outlook. The efforts to date have propelled key portfolio companies to become technology leaders. As these businesses work with investment partners to achieve additional recognition and scale, we see huge potential in the next phase of growth.”

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma faces a strategic turning point in AI adoption

AI in pharma is moving from operational support to strategic driver as companies prioritise messaging that delivers measurable prescriber impact.

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

The real problem holding back connected vehicle programmes

Vehicle identity is fast becoming a core infrastructure challenge, and a new bottleneck for OEMs aiming to scale software-defined platforms.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Search

Search